Review
Copyright ©The Author(s) 2018.
World J Transplantation. Oct 22, 2018; 8(6): 203-219
Published online Oct 22, 2018. doi: 10.5500/wjt.v8.i6.203
Figure 4
Figure 4 Response of complement 3 glomerulopathy subtypes to eculizumab therapy based on laboratory parameters and tissue (histopathological) response. A: Dense deposit disease response to eculizumab therapy[66]; B: Complement 3 glomerulonephritis response to eculizumab therapy[66]. CFH: Complement factor H; CFI: Complement factor I; C3Nef: C3 nephritic factor.